SIGMAR1 and lip and oral cavity carcinoma: Beyond suggesting potential immunomodulatory roles for SIGMAR1 in oral cancer, which are reflective of its poorer prognosis, our study provides novel evidence indicating that SIGMAR1 acts as a positive regulator of PD-L1 expression, thereby exacerbating chemoresistance in human oral cancer.